Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues...
Grand Pharmaceutical
Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...
Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights
Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to...
Telix Pharmaceuticals’ TLX591-CDx Approved in Europe via Decentralized Procedure
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that the marketing filing in Europe via...
Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in...
Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma
In a significant development in the alternative asset management sector, companies such as Blackstone and...
Grand Pharmaceutical’s GPN01768 Accepted for Review by NMPA for Demodex Blepharitis Treatment
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that the National Medical Products Administration...
Grand Pharmaceutical’s STC3141 Sepsis Therapy Completes Phase II Patient Enrollment
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the completion of patient enrollment...
Grand Pharmaceutical Group Receives NMPA Approval for NOVASYNC HYBRID SYSTM
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that it has received marketing...
Grand Pharmaceutical Group Secures Licensing Agreement for CORXEL’s Nasal Sprays in Greater China
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced a significant licensing agreement with...
Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status
Holland-based Xeltis AG has announced the enrollment of the first patient in a US-staged pivotal...
Grand Pharmaceutical Group Expands Distribution Partnership with Sirtex Medical in China
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...
China Grand Pharmaceutical Receives NMPA Approval for Innovative Adjustable Thrombectomy Stent
China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has announced that it has...
CGP’s 2024 Interim Report Shows Robust Growth in Revenues and Profits, Highlighting R&D Focus
HONG KONG—China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HKG: 0512) has released its interim...
China Grand Pharmaceutical Expands with Mitsubishi Tanabe Pharma and Baiji Pharma Acquisitions
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the completion of...
Grand Pharmaceutical Gets Nod for Phase II Sepsis Study of STC3141 in China
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced that it has...
Grand Pharmaceutical Group Ltd’s SIR-Spheres Set to Reach Wider Patient Base Through MediTrust Health Deal
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...
CGP’s GPN00884 Myopia Drug Enters Phase I Clinical Trial with First Patient Dosed
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the commencement of...
Grand Pharma Receives NMPA Approval for Global Phase III Study of RDC ITM-11 in GEP-NETs
Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced...